Fig. 5: In vivo characterization of HuJovi-1 CAR and KFN CAR.
From: Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies
a Schematic of NSG model with 2.5e6 HPB-ALL cells/animal (n = 6/group). b Median total flux radiance of HPB-ALL TRBC2 tumor burden (from a). Two-way ANOVA with Dunnett’s post test against KFN CAR, ***p < 0.001, ****p < 0.0001. Data shown as median with 95% CI. c Kaplan-Meier survival curve (cut-off 1e9 p/s/cm2/sr) (from a). Log-rank test ***p < 0.001. d (from left) HPB-ALL count in CAR treated mice; % of TRBC2 expressing cells in residual HPB-ALL population; human T cell count (CD3+) in treated mice; % RQR8+ (CAR) T cells in CD3+ population. One-way ANOVA with Dunnett’s post-test. *P < 0.05, **P < 0.01, ****P < 0.0001. Data shown as mean ± SD. e Schematic of NSG model with 5e6 Jurkat TRBC1 or 1e6 Jurkat TRBC2 cells/animal (n = 6/group). f (left) Median total radiance of Jurkat TRBC1 tumor burden. Two-way ANOVA with Dunnett’s post-test against HuJovi-1 CAR, **p < 0.01. Data shown as median with 95% CI. (right) Kaplan-Meier survival curve (cut-off 1e9 p/s/cm2/sr). # 1 mouse from aCD19 CAR at d34 and remaining mice from the non-transduced group at d55, sacrificed due to xenogeneic graft versus host disease. Log-rank test **p < 0.01. g (left) Median total radiance of Jurkat TRBC2 tumor burden. Two-way ANOVA with Dunnett’s post-test against KFN CAR, ****p < 0.0001. Data shown as median with 95% CI. (right) Kaplan-Meier survival curve (cut-off 1e9 p/s/cm2/sr). Log-rank test ***p < 0.001. Source data and exact p values are provided as a Source Data file.
